ArchiveApril 2018

Alemtuzumab, is one course enough?

…… data suggest that induction of disease remission for some patients might occur following just one dose of alemtuzumab.  Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS. J Neurol. 2018 Apr 17. doi: 10.1007/s00415-018-8845-4. [Epub ahead...

Another CD20 depleting agent shows efficacy

First there was rituximab (part mouse, part human), then there was ocrelizumab (largely human and a tiny bit mouse) and now there is ofatumumab (which is all human) as yet another B cell depleting antibody. Ofatumumab was being developed as an infusion but this was put on hold and studies were generated using a formulation injected under the skin and it (lower dose) was dosed much more frequently...

AAN2018: Laquinimod joins the PPMS graveyard

I am just back from LaLa Land and the AAN2018 meeting. I am feeling exhausted, MSed-out, conferenced-out and very concerned about the future of neurology (more on this on my Medium post).  The AAN2018 was far too long, too spread-out (the venue was cavernous with rooms that were in general too large) and too expensive (conference fees, LA hotels, restaurants, regional wines and flights)...

Changing Gut microbes with a probiotic

Its AAN this week and ProfG and many of the other Neuros are in LaLa Land to get their annual fill of all things neurology.  What interests you this year? As soon as the microbiome (Gut Microbe) appeared it was obvious that the scammers would be there to make money off vulnerable people. People will asked to pay money to have their bowels cleared and the they have to eat a feacal extract to...

Improving the taste of cannabis spray

AIM: Complaints about Δ9-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex®; GW Pharma Ltd, Sailsbury, UK) in the management of multiple sclerosis spasticity include unpleasant taste and oral mucosal anomalies. This pilot study assessed the use of sugar-free chewing gum and/or a refrigerated bottle of THC:CBD oromucosal spray to mitigate these effects. MATERIALS...

MSTV has launched!

It’s MS Awareness Week from the 23rd-29th April and the MS Trust have launched a new YouTube channel and project for young people aged 11 to 17 who are affected by MS. “Getting your head around MS can be hard enough when you’re an adult. But for young people it can be devastating, so good quality information is vital. Therefore we’ve been working with young people to understand the...

MS@thelimits 2018

Do you want to attend the MS@thelimits 2018 meeting?  This year the focus is on cellular therapies, comorbidities and trials in more advanced MS.  Have a look at the programme.  Following on the success of last year’s MS at the limits meeting in London we are holding a second meeting this November.  The feedback we got from last year’s meeting was...

For those not there. Here is At the Limits 2017

If you don’t live near London, fear not, because the meeting will no doubt be filmed,  Indeed last year it was “live streamed” and the events went online. You can watch it, if you follow the links here However, because the organizers i.e. ProfG and Prof Carroll had got enough sponsors, the event could not be hosted on the Lancet website. Hopefully, the Profs will learn from...

Pharma comes out

Last year we spent quite some time hastling  Eli Lilly about the fact that they had not published the data about tabalumab (anti-BAFF) in MS. Atacicicept (anti-BAFF & APRIL) made MS worse. SO what happened with Tabalumab. I guess we now find out Maria Silk , Eric Nantz Efficacy and Safety of Tabalumab in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized, Double-Blind...

PML risk in fingolimod

Progressive multifocal leukoencephalopathy after fingolimod treatment Joseph R. Berger, Bruce A. Cree, Benjamin Greenberg, Bernhard Hemmer, Brian J. Ward, Victor M. Dong and Martin Merschhemke First published April 18, 2018, DOI: loads Abstract Objective We describe the characteristics of the 15 patients with fingolimod-associated progressive multifocal leukoencephalopathy (PML) identified from...

Translate

Categories

Recent Posts

Recent Comments

Archives